本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Arcutis Biotherapeutics Inc.

25.72
+2.219.40%
成交量:319.71萬
成交額:7,999.48萬
市值:32.17億
市盈率:119.40
高:25.74
開:23.63
低:23.63
收:23.51
52周最高:31.77
52周最低:16.57
股本:1.25億
流通股本:1.11億
量比:1.43
換手率:2.88%
股息:- -
股息率:- -
每股收益(TTM):0.2154
每股收益(LYR):-0.1269
淨資產收益率:15.86%
總資產收益率:5.09%
市淨率:14.58
市盈率(LYR):-202.74

資料載入中...

2022/08/09

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/08/08

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/08/08

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/08/05

重要事件披露

8-K - Current report
2022/08/04

重要事件披露

8-K - Current report
2022/08/04

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/08/02

重要事件披露

8-K - Current report
2022/06/28

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/06/09

重要事件披露

8-K - Current report
2022/06/02

重要事件披露

8-K - Current report
2022/05/27

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/05/05

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/05/05

重要事件披露

8-K - Current report
2022/04/08

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/03/03

[修訂]年度報告

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/02/22

重要事件披露

8-K - Current report
2022/02/22

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/02/22

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/12/23

重要事件披露

8-K - Current report